Аңдатпа
Introduction: To detect the morphological parameters of ovarian masses and the accuracy of the risk of mali gnancy index (RMI) in diagnosing ovarian malignancy.Material and methods: 264 women in 3 groups (reproductive, premenopausal, and postmenopausal) pre sented with ovarian masses and scheduled for surgery were included in this study.The participants' preoperative RMI was compared to the postoperative histology (gold standard) to detect the accuracy of RMI in diagnosing ovarian malignancy.Results: The incidence of malignant and benign ovarian tumours in the reproductive group was 9.1% and 90.9%, respectively, while it was 35.2% and 64.8%, respectively, in the premenopausal group, and 35.2%, and 64.8%, respectively, in the postmenopausal group.The incidence of malignant ovarian tumours was significantly higher in the premenopausal (35.2%) and postmenopausal (35.2%) groups compared to the reproductive group (9.1%), (p = 0.0008, and p = 0.0008, respectively).The receiver operating characteristic curve showed that RMI at cutoff value > 247.5 had 82.9% sensitivity, 100% specificity, 100% positive predictive value (PPV), and 98.1% negative predictive value (NPV) in diagnosing ovarian malignancy in the 3 studied groups (AUC 0.955, p < 0.001).There was significant positive correlation between the participants' age, and RMI (p = 0.001), and between participants' cancer antigen125 (CA125) and RMI (p < 0.0001) in the ovarian malignancy group.Conclusions: The multimodal RMI is an effective tool for primary evaluation of suspected ovarian masses.Risk malignancy index at cutoff value > 247.5 had the best performance (82.9% sensitivity, 100% specificity, 100% PPV, and 98.1% NPV) in diagnosing ovarian malignancy in the 3 studied groups.There was significant posi tive correlation between participants' age, and RMI, and between participants' CA125 and RMI, in the studied malignant ovarian tumours.Key words: morphological, ovarian, risk malignancy index, RMI, cancer.Pelvic assessment, tumour markers, and radiologi cal investigations have been proposed for screening and early detection of ovarian tumours, but each parameter is not sensitive nor specific when considered separately.The ovarian cancer screening trial UK Collaborative Trial of Ovarian Cancer Screening recommended screening for ovarian malignancy using serum cancer antigen125 (CA125) with transvaginal sonography (TVS) (multi modal screening) to calculate the risk malignancy index (RMI) [5,6].The risk of malignancy index is calculated from the CA125 absolute value (IU/ml), menopausal status (M), and ultrasound findings (U) [5,6].Recently, Dora et al. evaluated the diagnostic perfor mance of RMI in women with adnexal masses and found RMI was simple and applicable tool in the primary eval